{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:08:01Z","timestamp":1766088481920,"version":"3.41.2"},"reference-count":40,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Data on long-term outcomes for men with prostate cancer treated according to current guidelines are limited. We aimed to estimate the long-term risk of death from prostate cancer and other causes in men with nonmetastatic prostate cancer who received primary treatment according to current guidelines. <jats:bold>Methods:<\/jats:bold> Men with nonmetastatic prostate cancer registered in the National Prostate Cancer Register of Sweden from 2000 to 2020, who received primary treatment according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer, Version 4.2023, were included and followed until December 31, 2022. The risk of death from prostate cancer and other causes up to 30 years was estimated according to risk category and life expectancy using a state transition simulation model. <jats:bold>Results:<\/jats:bold> A total of 62,839 men received primary treatment according to the NCCN Guidelines. The simulated 15-year prostate cancer mortality per risk category ranged from 5.5% (95% CI, 4.8%\u20136.2%) in men with low-risk cancer to 22% (95% CI, 21%\u201324%) in men with very high-risk cancer. Simulated 30-year prostate cancer mortality ranged from 12% (95% CI, 10%\u201314%) in men with low-risk cancer to 30% (95% CI, 29%\u201332%) in men with very high-risk cancer, whereas death from other causes ranged from 77% (95% CI, 74%\u201380%) to 63% (95% CI, 59%\u201367%), respectively. <jats:bold>Conclusions:<\/jats:bold> Men with nonmetastatic prostate cancer who received primary treatment according to current guidelines were up to 6 times more likely to die of other causes than from their cancer. These estimates provide realistic but high expectations of the outcomes of modern treatment and can serve as benchmarks for clinical outcome reporting.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7022","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:30:26Z","timestamp":1752150626000},"source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer"],"prefix":"10.6004","volume":"23","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Division of Experimental Oncology\/Unit of Urology, URI Institution, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri Wilberg","family":"Orrason","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Gedeborg","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Westerberg","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I,  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394\u2013424."},{"key":"B2","article-title":"Cancer facts & figures 2020","unstructured":"American Cancer Society. Cancer facts & figures 2020. Accessed March 25, 2024. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html"},{"key":"B3","series-title":"BMC Med","first-page":"31","article-title":"The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam VJ","year":"2018","unstructured":"Gnanapragasam VJ, Bratt O, Muir K,  The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med 2018;16:31."},{"key":"B4","series-title":"Eur Urol","first-page":"88","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider JR","year":"2013","unstructured":"Rider JR, Sandin F, Andr\u00e9n O,  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013;63:88\u201396."},{"key":"B5","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1473","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity \u2013 United States, 2001\u20132017","volume":"69","author":"Siegel DA","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB,  Prostate cancer incidence and survival, by stage and race\/ethnicity \u2013 United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep 2020;69:1473\u20131480."},{"key":"B6","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2023","author":"Schaeffer EM","unstructured":"Schaeffer EM, Srinivas S, Adra N,  NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2023. Accessed March 25, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B7","series-title":"PLoS Med","first-page":"e1002758","article-title":"Individual prognosis at diagnosis in nonmetastatic prostate cancer: development and external validation of the PREDICT Prostate multivariable model","volume":"16","author":"Thurtle DR","year":"2019","unstructured":"Thurtle DR, Greenberg DC, Lee LS,  Individual prognosis at diagnosis in nonmetastatic prostate cancer: development and external validation of the PREDICT Prostate multivariable model. PLoS Med 2019;16:e1002758."},{"key":"B8","series-title":"Cancer","first-page":"5039","article-title":"The CAPRA\u2010S score","volume":"117","author":"Cooperberg MR","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR. The CAPRA\u2010S score. Cancer 2011;117:5039\u20135046."},{"key":"B9","series-title":"Scand J Urol","first-page":"265","article-title":"The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease","volume":"56","author":"Bratt O","year":"2022","unstructured":"Bratt O, Carlsson S, Fransson P,  The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol 2022;56:265\u2013273."},{"key":"B10","series-title":"Scand J Urol","first-page":"210211","article-title":"2023\/2024 update of the national prostate cancer guidelines in Sweden","volume":"59","author":"Stranne J","year":"2024","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol 2024;59:210211."},{"key":"B11","series-title":"Scand J Urol","first-page":"190192","article-title":"How to improve cancer care by use of guidelines and quality registers","volume":"59","author":"Stattin P","year":"2024","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol 2024;59:190192."},{"key":"B12","series-title":"Int J Epidemiol","first-page":"73","article-title":"Cohort profile update: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base\u2014a refined prostate cancer trajectory","volume":"45","author":"Van Hemelrijck M","year":"2016","unstructured":"Van Hemelrijck M, Garmo H, Wigertz A,  Cohort profile update: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base\u2014a refined prostate cancer trajectory. Int J Epidemiol 2016;45:73\u201382."},{"key":"B13","series-title":"Eur J Cancer","first-page":"101","article-title":"Evaluation of data quality in the National Prostate Cancer Register of Sweden","volume":"51","author":"Tomic K","year":"2015","unstructured":"Tomic K, Sandin F, Wigertz A,  Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer 2015;51:101\u2013111."},{"key":"B14","series-title":"Acta Oncol","first-page":"158","article-title":"Capture rate and representativity of the National Prostate Cancer Register of Sweden","volume":"54","author":"Tomic K","year":"2015","unstructured":"Tomic K, Berglund A, Robinson D,  Capture rate and representativity of the National Prostate Cancer Register of Sweden. Acta Oncol 2015;54:158\u2013163."},{"key":"B15","series-title":"Scand J Urol","first-page":"207209","article-title":"Assessment of variability in life expectancy in older men by use of new comorbidity indices. A nationwide population-based study","volume":"59","author":"Westerberg M","year":"2024","unstructured":"Westerberg M, Ahlberg M, Orrason AW, Gedeborg R. Assessment of variability in life expectancy in older men by use of new comorbidity indices. A nationwide population-based study. Scand J Urol 2024;59:207209."},{"key":"B16","series-title":"Epidemiology","first-page":"607","article-title":"An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts","volume":"32","author":"Gedeborg R","year":"2021","unstructured":"Gedeborg R, Sund M, Lambe M,  An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology 2021;32:607\u2013615."},{"key":"B17","series-title":"BMC Med Inform Decis Mak","first-page":"35","article-title":"Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males","volume":"22","author":"Van Hemelrijck M","year":"2022","unstructured":"Van Hemelrijck M, Ventimiglia E, Robinson D,  Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak 2022;22:35."},{"key":"B18","series-title":"PLoS One","first-page":"e0296804","article-title":"Development and validation of a multidimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study","volume":"19","author":"Westerberg M","year":"2024","unstructured":"Westerberg M, Irenaeus S, Garmo H,  Development and validation of a multidimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One 2024;19:e0296804."},{"key":"B19","series-title":"Eur Urol","first-page":"502","article-title":"Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study","volume":"73","author":"Robinson D","year":"2018","unstructured":"Robinson D, Garmo H, Lissbrant IF,  Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol 2018;73:502\u2013511."},{"key":"B20","series-title":"BMC Med Inform Decis Mak","first-page":"103","article-title":"How to measure temporal changes in care pathways for chronic diseases using health care registry data","volume":"19","author":"Ventimiglia E","year":"2019","unstructured":"Ventimiglia E, Van Hemelrijck M, Lindhagen L,  How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak 2019;19:103."},{"key":"B21","series-title":"N Engl J Med","first-page":"1547","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy FC","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA,  Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388:1547\u20131558."},{"key":"B22","unstructured":"European Society of Cardiology. 2022 ESC Guidelines on cardio-oncology. Accessed March 25, 2024. Available at: https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Cardio-oncology-guidelines"},{"key":"B23","series-title":"Eur Urol","first-page":"661","article-title":"Clinical impact of the predict prostate risk communication tool in men newly diagnosed with nonmetastatic prostate cancer: a multicentre randomised controlled trial","volume":"80","author":"Thurtle D","year":"2021","unstructured":"Thurtle D, Jenkins V, Freeman A,  Clinical impact of the predict prostate risk communication tool in men newly diagnosed with nonmetastatic prostate cancer: a multicentre randomised controlled trial. Eur Urol 2021;80:661\u2013669."},{"key":"B24","article-title":"Country comparison: Sweden\/United States of America","unstructured":"Worlddata.info. Country comparison: Sweden\/United States of America. Accessed March 25, 2024. Available at: https:\/\/www.worlddata.info\/country-comparison.php?country1=SWE&country2=USA"},{"key":"B25","article-title":"How does the quality of the U.S. health system compare to other countries? Peterson-KFF Health System Tracker","author":"Kurani N","unstructured":"Kurani N, Wager E, Telesford I,  How does the quality of the U.S. health system compare to other countries? Peterson-KFF Health System Tracker. Accessed March 25, 2024. Available at: https:\/\/www.healthsystemtracker.org\/chart-collection\/quality-u-s-healthcare-system-compare-countries\/#longterm-health-outcomes"},{"key":"B26","series-title":"J Natl Cancer Inst","first-page":"1335","article-title":"Temporal trends in cause of death among Swedish and US men with prostate cancer","volume":"104","author":"Epstein MM","year":"2012","unstructured":"Epstein MM, Edgren G, Rider JR,  Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104:1335\u20131342."},{"key":"B27","unstructured":"International Agency for Research on Cancer. Global Cancer Observatory. Accessed March 25, 2024. Available at: https:\/\/gco.iarc.fr\/en"},{"key":"B28","series-title":"N Engl J Med","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M,  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737\u2013746."},{"key":"B29","series-title":"Lancet","first-page":"1695","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J,  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 2022;399:1695\u20131707."},{"key":"B30","series-title":"Eur Urol","first-page":"243","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20132020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet N","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E,  EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20132020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79:243\u2013262."},{"key":"B31","series-title":"J Urol","first-page":"10","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham JA","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA,  Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10\u201318."},{"key":"B32","series-title":"JAMA Netw Open","first-page":"e2231015","article-title":"Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden","volume":"5","author":"Ventimiglia E","year":"2022","unstructured":"Ventimiglia E, Bill-Axelson A, Bratt O,  Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden. JAMA Netw Open 2022;5:e2231015."},{"key":"B33","series-title":"Eur Urol","first-page":"756","article-title":"Predicting life expectancy in men diagnosed with prostate cancer","volume":"68","author":"Sammon JD","year":"2015","unstructured":"Sammon JD, Abdollah F, D\u2019Amico A,  Predicting life expectancy in men diagnosed with prostate cancer. Eur Urol 2015;68:756\u2013765."},{"key":"B34","series-title":"Res Social Adm Pharm","first-page":"704","article-title":"The use of pictograms in the health care: a literature review","volume":"10","author":"Barros IMC","year":"2014","unstructured":"Barros IMC, Alc\u00e2ntara TS, Mesquita AR,  The use of pictograms in the health care: a literature review. Res Social Adm Pharm 2014;10:704\u2013719."},{"key":"B35","series-title":"J Surg Oncol","first-page":"867","article-title":"Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study","volume":"124","author":"Thomsen FB","year":"2021","unstructured":"Thomsen FB, Garmo H, Brasso K,  Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. J Surg Oncol 2021;124:867\u2013875."},{"key":"B36","series-title":"Scand J Urol","first-page":"426","article-title":"Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories","volume":"48","author":"Ohmann EL","year":"2014","unstructured":"Ohmann EL, Loeb S, Robinson D,  Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol 2014;48:426\u2013435."},{"key":"B37","series-title":"J Urol","first-page":"28","article-title":"The Will Rogers phenomenon in urological oncology","volume":"179","author":"Gofrit ON","year":"2008","unstructured":"Gofrit ON, Zorn KC, Steinberg GD,  The Will Rogers phenomenon in urological oncology. J Urol 2008;179:28\u201333."},{"key":"B38","series-title":"BJU Int","first-page":"421","article-title":"Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study","volume":"123","author":"Cazzaniga W","year":"2019","unstructured":"Cazzaniga W, Garmo H, Robinson D,  Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int 2019;123:421\u2013428."},{"key":"B39","series-title":"BJU Int","first-page":"248","article-title":"Gleason inflation 1998-2011: a registry study of 97 168 men","volume":"115","author":"Danneman D","year":"2015","unstructured":"Danneman D, Drevin L, Robinson D,  Gleason inflation 1998-2011: a registry study of 97 168 men. BJU Int 2015;115:248\u2013255."},{"key":"B40","series-title":"BJU Int","first-page":"486","article-title":"Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden","volume":"131","author":"Orrason AW","year":"2023","unstructured":"Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int 2023;131:486\u2013493."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257022.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257022.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257022.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:30:26Z","timestamp":1752150626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257022.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7022","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}